Full Press Release Details
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric ™ and EFECT ™ Therapeutic Platforms.
ZYME
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric ™ and EFECT ™ Therapeutic Platforms
Key Takeaway: Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric ™ and EFECT ™ Therapeutic Platforms
Price reaction · baseline $32.04 (2021-08-02 close) · hit after-hours · 1 other ZYME headline(s) in the window, move may be shared
day 0 close
-0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers